Updates in Cytomegalovirus Prevention in Allogeneic Hematopoietic Stem Cell Transplant Recipients

Presented by, Gina Migneco PharmD

While cytometalovirus (CMV) is a common infection that most patients are exposed to in childhood, CMV infections or reactivations are a known potential complication in the hematology oncology population. In the context of immunocompromise, CMV can lead to lower survival and higher rates of other infections and/or graft vs host disease. This presentation will cover different patient specific and disease specific risk factors for CMV infection and reactivation. In addition, the most up to date evidence for prevention strategies will be presented, with special focus on the most recent data for the use of letermovir in this population.

UAN: 0036-9999-24-006-L01-P/T

March 6, 2024
6:00 - 7:30 pm
Dinner starts at 6:00 pm
CE Starts at 6:30 pm
Joseph R. Robertson Collaborative Life Sciences Building, 2S060, main pharmacy lecture hall

OSHP Program Fee
OSHP/OSPA Members: No Fee | Non Members: $ 20 per person
Advanced registration is required.

Dinner will be provided

CE Type: Disease state management/Drug therapy

Gina Migneco, PharmD
Oncology Pharmacist, Oregon Health & Sciences University

Dr. Migneco graduated from the University of Maryland School of Pharmacy with her PharmD, and completed her PGY1 in pharmacy practice and PGY2 training in oncology at Oregon Health& Science University(OHSU). She is currently a hematology/bone marrow transplant clinical pharmacist at OHSU, with ongoing interest in CAR-T therapy and CMV prevention.

Meet Our Exhibitors!